• Users Online: 454
  • Print this page
  • Email this page
Year : 2020  |  Volume : 10  |  Issue : 1  |  Page : 19-25

Nonarthroplasty management of osteonecrosis of the femoral head

1 Duke University Department of Orthopaedic Surgery, Durham, NC, USA
2 Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, IL, USA

Correspondence Address:
Mr. Harrison R Ferlauto
Duke University School of Medicine, 8 Searle Center Drive, Durham, NC 27710
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/DORJ.DORJ_8_20

Rights and Permissions

It is estimated that 10,000–20,000 new cases of osteonecrosis of the femoral head (ONFH) are diagnosed annually in the United States. Left untreated, this disease results in progressive collapse of the femoral head and destruction of the hip joint, resulting in the need for total hip arthroplasty (THA). However, in younger patients with ONFH, initial treatment with THA is not a practical option because these patients typically outlive the life of their implant, and thus may require multiple revision operations. Therefore, a variety of nonarthroplasty treatments for ONFH have been developed to slow the progression of disease and prolong the time that a person can go before requiring THA. These nonarthroplasty treatments are grouped into three general categories: Pharmacologic, nonpharmacologic/nonoperative, and operative. However, there is no consensus as to the optimal nonarthroplasty management of ONFH. This article provides a review of the literature regarding nonarthroplasty management of ONFH.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded317    
    Comments [Add]    

Recommend this journal